Streetwise Reports' Article Archives — July 2020 back to current month (30)
Meridian Bioscience's business segments, revenue and growth as well as COVID-19's positive impact on them are reviewed in an H.C. Wainwright & Co. report.
CloudMD reported it entered into a definitive agreement to acquire South Surrey Medical Clinic in Metro Vancouver in a combination stock and cash deal valued at CA$700,000.
Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation.
Shares of TCR2 Therapeutics traded 30% higher after the firm released encouraging results from the Phase 1 portion of its clinical study of TC-210 in treating advanced mesothelin-expressing solid tumors.
Shares of Milestone Pharmaceuticals traded 150% higher after the company reported regulatory guidance and updated its clinical development plan for etripamil nasal spray designed for self-administered use in PSVT treatment.
A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report.
Shares of HCA Healthcare traded more than 10% higher after the company reported Q2/20 financial results and advised it has seen a gradual rise in patient volumes in May and June for elective and non-emergency procedures.
Shares of Owens & Minor reached a new 52-week high after the company reported preliminary Q2/20 results and raised FY/20 earnings guidance.
Loop Insights continues to educate governments and venue operators around the world about its easily implemented platform.
With this transaction, CloudMD Software & Services will become Canada's first telemedicine company with both primary care and mental health care components.
Shares of Dynavax Technologies reached a new 52-week high after the company reported that it is collaborating with Mount Sinai to develop a universal influenza vaccine candidate with CpG 1018 adjuvant.
In the time of Covid-19, Peter Epstein of Epstein Research breaks down the investment opportunity offered by CloudMD.
Patriot One Technologies reported its Xtract AI division is working with Canexia Health to increase access to cancer testing as part of the Digital Technology Supercluster COVID-19 Program project.
AC Immune SA shares set a new 52-week high after the Swiss biotech firm reported that interim data from its Phase 1b/2a phospho-Tau Alzheimer's Vaccine study reconfirms promising safety and Tau-specific immunogenicity observed in the prior clinical trial.
Shares of Taiwan Liposome Co. reached a new 52-week high after the company released a manuscript describing how its inhalable liposomal hydroxychloroquine may provide clinical benefit and offer a potential treatment for Covid-19.
Reliq Health Technologies' agreement with digiiMED makes its platform available to more than 200,000 patients.
Potential Covid-19 Treatment Is Ready for Prime Time (07/14/2020)
Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record.
Shares of INmune Bio reached a new 52-week high after the company reported interim data from its Phase 1b study of XPro1595 that demonstrated decreased neuroinflammation in Alzheimer's patients.
Echelon Capital Markets initiates coverage and explains why it is bullish on CloudMD Software & Services.
ProMIS Neurosciences and its collaborator make their relationship official with a joint venture agreement.
Shares of BioNTech SE traded 15% higher after the company reported that, together with its partner Pfizer, it has received FDA Fast Track designation for two separate mRNA-based vaccine candidates against SARS-CoV-2.
Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program.
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVIDô, its COVID-19 vaccine candidate.
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report.
Preclinical COVID-19 Vaccine Data 'Encouraging' (07/08/2020)
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report.
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications.
Analyst: G1 Minimizes the Carnage of Chemotherapy (07/01/2020)
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA.
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report.
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2.
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients.
|"We expect PMN to commence formal Phase 1 testing later this year."|